Home » Market News » DirectorsTalk Highlights » Top Reasons for Hospital Admissions in Lupus
Immupharma Plc

Top Reasons for Hospital Admissions in Lupus

A 20-year long retrospective analysis of 814 systemic lupus erythematosus (SLE)-related hospitalizations of 339 SLE patients, reveals some interesting new patterns in lupus disease from hospitalization rates to disease complications and mortality.

Published in the July 12 issue of Lupus, this study identified the most relevant cause of death in lupus patients was due to complications from associated antiphospholipid syndrome  (APS), even though the main reasons for hospital admissions remained constant over the 20-year period of the study.

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.